Abstract: After more than 10 years of development, renal denervation (RDN) has become an interventional method for the treatment of hypertension. As the “third pillar” of hypertension management, the research and development process has been bumpy and long, with controversies, challenges and consensus. In terms of different views on basic theory, technology and efficacy evaluation, it is suggested to take science and data as the criterion in disputes, keep a clear mind, and obtain consensus from practice.